

Fecha del CVA
24/04/2025
Parte A. DATOS PERSONALES

Nombre *	Nadia		
Apellidos *	Hindi Muñiz		
Sexo *	No Contesta	Fecha de Nacimiento *	
DNI/NIE/Pasaporte *		Teléfono *	
URL Web			
Dirección Email			
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0002-5864-762X	
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Facultativo Especialista de Área		
Fecha inicio	2021		
Organismo / Institución	Hospital General de Villalba y HU Fundación Jimenez Diaz		
Departamento / Centro			
País		Teléfono	
Palabras clave			

A.2. Situación profesional anterior

Periodo	Puesto / Institución / País
2015 - 2020	Facultativo Especialista de Area / Hospital Universitario Virgen del Rocío
2013 - 2015	Clinical Fellow / Istituto Nazionale dei Tumori (Milán)
2012 - 2013	Facultativo Especialista de Área / Hospital Universitario La Paz
2008 - 2012	Medico Interno Residente / Hospital Universitario La Paz

A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Máster en Oncología Molecular	Centro Nacional de Investigaciones Oncológicas	2013
Licenciado en Medicina y Cirugía	Universidad Autónoma de Madrid	2007

Parte C. MÉRITOS MÁS RELEVANTES
C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citas

- Artículo científico.** J Martin-Broto; A Redondo; DS Moura; et al; N Hindi. 2022. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nat Commun. 13-1, pp.6278. <https://doi.org/10.1038/s41467-022-33975-6>.
- Artículo científico.** J Martin-Broto; R Diaz-Betveritge; DS Moura; et al; N Hindi. 2025. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). J Clin Oncol. 43-3, pp.297-307.
- Artículo científico.** E Palmerini; A Lopez-Pousa; G Grignani; A Redondo; N Hindi; et al. 2025. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. Cancer. 131-1, pp.e35628.

- 4 **Artículo científico.** DS Moura; JM Lopez-Marti; I Benesova; et al; J Martin-Broto. 2024. Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial. Clin Can Res. 30-22, pp.5192-5206.
- 5 **Artículo científico.** JL Mondaza-Hernandez; N Hindi; A Fernandez-Serra; et al. 2024. Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma. Ther Adv Med Oncol .16-17588359241293951.
- 6 **Artículo científico.** DS Moura; D Lopez Lopez; D di Lernia; et al; J Martin-Broto. 2024. Shared germline genomic variants in two patients with double primary gastrointestinal stromal tumours (GISTs). J Med Genet .61-10, pp.927-934.
- 7 **Artículo científico.** J Carrillo-Garcia; N Hindi; Magda Conceicao; et al. 2024. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. Eur J Cancer .209, pp.114270.
- 8 **Artículo científico.** J Martin Broto; N Hindi; DS Moura. 2024. Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions. Curr Opin Oncol .36-4, pp.269-275.
- 9 **Artículo científico.** DS Moura; JL Mondaaza-Hernandez; P Sanchez-Bustos; et al; J Martin-Broto. 2024. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study. Cell Mol Life Sci. 81-1, pp.219.
- 10 **Artículo científico.** J Carrillo-García; S Lacerenza; N Hindi; et al. 2024. Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients. Cytokine. 177-156542.
- 11 **Artículo científico.** JY Blay; P Casali; I Ray-Coquard; et al; et al; (21/22) N Hindi. 2024. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN. Lancet Reg Health Eur. 39-100861.
- 12 **Artículo científico.** Javier; Alicia; Ricardo; et al; (17/17) Nadia. 2024. Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma. Therapeutic Advances in Medical Oncology. 16. <https://doi.org/10.1177/17588359231225044>
- 13 **Artículo científico.** J Carrillo-García; S Lacerenza; N Hindi; et al. 2024. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain. Ther Adv Med Oncol. 16-17588359231220611.
- 14 **Artículo científico.** N Hindi; A Razak; E Rosenbaum; et al. 2023. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open. 8-6, pp.102045.
- 15 **Artículo científico.** C Torrado; M Camaño; N Hindi; et al. 2023. Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature. Cancers (Basel). 15-21, pp.5187.
- 16 **Artículo científico.** Javier; Jeronimo; David; et al; (19/19) Nadia. 2023. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDJB2A. Signal transduction and targeted therapy. 8-1. <https://doi.org/10.1038/s41392-023-01661-8>
- 17 **Artículo científico.** S Attia; V Villalobos; N Hindi; et al. 2023. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers (Basel). 15-19, pp.4871.
- 18 **Artículo científico.** Javier; Claudia; (3/27) Nadia; et al; Virginia. 2023. REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. <https://doi.org/10.1186/s12943-023-01832-9>.
- 19 **Artículo científico.** Nadia Hindi; Nadia Laack; Kevin Hong; Peter Hohenberger. 2023. Local Therapies for Metastatic Sarcoma: Why, When, and How?. Am Soc Clin Oncol Educ Book. 43, pp.e390554..
- 20 **Artículo científico.** Roberta Sanfilippo; Nadia Hindi; Josefina Cruz Jurado; et al. 2023. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncology. 9-5, pp.656-663.

- 21 **Artículo científico.** N Hindi; J Carrillo-Garcia; E Blanco-Alcaina; et al; J Martin-Broto. 2023. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. *Int J Mol Sci.* 24-1, pp.856. <https://doi.org/10.3390/ijms24010856>
- 22 **Artículo científico.** ; N Hindi; R Haas. 2022. Management of Synovial Sarcoma and Myxoid Liposarcoma. *Surg Oncol Clin N Am.* 31-3, pp.547-558. <https://doi.org/10.1016/j.soc.2022.03.012>
- 23 **Artículo científico.** JY Blay; E Palmerini; J Bollard; et al; et al. 2022. SELNET clinical practice guidelines for bone sarcoma. *Crit Rev Oncol Hematol.* 174, pp.10368. <https://doi.org/10.1016/j.critrevonc.2022.103685>
- 24 **Artículo científico.** JY Blay; N Hindi; J Bollard; et al. 2022. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. *Cancer Treat Rev.* 102, pp.102312.
- 25 **Artículo científico.** PG Casali; JY Blay; N Abecassis; et al; et al. 2022. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology.* 33-1, pp.20-33.
- 26 **Artículo científico.** SJ Strauss; AM Frezza; N Abecassis; et al; et al. 2021. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology.* 32-12, pp.1520-1536.
- 27 **Artículo científico.** A Gronchi; A Miah; AP dei Tos; et al; et al. 2021. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* S0923-7534(21)02184.
- 28 **Artículo científico.** N Hindi; J Martin-Broto. 2021. What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. *Curr Opin Oncol.* 33-4, pp.329-335.
- 29 **Artículo científico.** N Hindi; I Carrasco-Garcia; A Sanchez-Camacho; et al; J Martin-Broto. 2020. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. *Cancers (Basel).* 12-12, pp.3740.
- 30 **Artículo científico.** J Martin-Broto; N Hindi; G Grignani; et al; JA Lopez-Martin. 2020. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. *Journal for Immunotherapy of Cancer.* 8-2, pp.e001561.
- 31 **Artículo científico.** Martin-Broto J; Hindi N; Aguiar S Jr; et al; Blay JY. 2020. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. *The Oncologist.*
- 32 **Artículo científico.** Martin-Broto J; Cruz J; Penel N; et al; Stacchiotti S. 2020. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. *The Lancet. Oncology.* 21(3), pp.456-466. ISSN 1474-5488. [https://doi.org/10.1016/S1470-2045\(19\)30826-5](https://doi.org/10.1016/S1470-2045(19)30826-5)
- 33 **Artículo científico.** Stacchiotti S; Ferrari S; Redondo A; et al; Martin-Broto J. 2019. Pazopanib for treatment of advanced extraskelletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *The Lancet. Oncology.* 20(9), pp.1252-1262. ISSN 1470-2045. [https://doi.org/10.1016/S1470-2045\(19\)30319-5](https://doi.org/10.1016/S1470-2045(19)30319-5)
- 34 **Artículo científico.** Fucà G; Hindi N; Ray-Coquard I; et al; Sanfilippo R. 2019. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *The oncologist.* 24(7), pp.e536-e541. ISSN 1083-7159. <https://doi.org/10.1634/theoncologist.2018-0338>
- 35 **Artículo científico.** Martin-Broto J; Moura DS; Hindi N. 2019. Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply. *The Lancet. Oncology.* 20(3), pp.e128. ISSN 1470-2045. [https://doi.org/10.1016/S1470-2045\(19\)30080-4](https://doi.org/10.1016/S1470-2045(19)30080-4)
- 36 **Artículo científico.** Gronchi A; Hindi N; Cruz J; et al; Martin-Broto J. 2019. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine.* 9, pp.35-43. ISSN 2589-5370. <https://doi.org/10.1016/j.eclinm.2019.03.007>

- 37 Artículo científico.** J Martin-Broto; DS Moura; N Hindi. 2019. Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply. *Lancet Oncology*. 20-(3):e128..
- 38 Artículo científico.** Martin-Broto J; Stacchiotti S; Lopez-Pousa A; et al; Cruz J. 2019. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. *The Lancet. Oncology*. 20(1), pp.134-144. ISSN 1470-2045. [https://doi.org/10.1016/S1470-2045\(18\)30676-4](https://doi.org/10.1016/S1470-2045(18)30676-4)
- 39 Artículo científico.** Hindi N; Casali PG; Morosi C; et al; Stacchiotti S. 2015. Imatinib in advanced chordoma: A retrospective case series analysis. *European journal of cancer* (Oxford, England : 1990). 51(17), pp.2609-14. ISSN 0959-8049. <https://doi.org/10.1016/j.ejca.2015.07.038>